Sino Biopharm (1177.HK) Announces 2023 Annual Results
HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023.
- HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023.
- During the year, the Group recorded revenue of approximately RMB26.20 billion, an increase of approximately 0.7% over last year.
- The Board of Directors has recommended a final dividend payment of HK3 cents per share (2022: HK6 cents).
- Sino Biopharm is committed to "be a leading global pharmaceutical company through delivering innovative therapies for patients".